Revvity Unveils Next-Gen Cellular Imaging Innovation

Revvity Unveils Next-Gen Cellular Imaging Innovation

Revvity, Inc. is set to present its innovative Phenologic.AI™ software at SLAS2025. This event promises to be a pivotal moment for scientific advancements. The Phenologic.AI software seeks to transform cellular imaging workflows, enhancing capabilities for research and development in life sciences.

Understanding the Power of Phenologic.AI

Designed to integrate seamlessly with Revvity’s Harmony™ and Signals Image Artist™ software packages, Phenologic.AI leverages advanced deep-learning models to analyze brightfield images. This technology introduces an additional multiplexing channel and simplifies workflows for live cell analysis. Such significant advancements provide researchers with a powerful tool to better understand cellular behaviors and disease mechanisms.

The Benefits of Scalable and Efficient Analysis

Phenologic.AI not only offers objective analysis but also allows for streamlined data processing. This efficiency is critical for scientists looking to extract valuable insights from high-volume experiments. With the capability to integrate with the Revvity Signals Research Suite™, it provides deeper analytical capabilities, paving the way for enhanced data-driven decision-making in research labs.

Complementary Innovations at SLAS2025

During the SLAS2025 event, Revvity will also showcase cutting-edge products like the latest Harmony™ 5.3 software. This software enhances the management of high-content imaging data, making it quicker and more intuitive to navigate large datasets.

Explore Revvity’s Robust Portfolio at the Event

Attendees at Revvity’s booth, #1318, will discover over 40 innovative products from its life sciences portfolio. Solutions on display include automation systems, cellular research tools, liquid handling technologies, flow cytometry capabilities, and essential reagents. Each product is engineered to boost efficiency and spur innovation in drug discovery and development processes.

Driving Research Forward

Kevin Quick, Vice President of Platforms at Revvity, expressed enthusiasm about the event: "SLAS is a great opportunity to showcase our most innovative technologies and celebrated brands. Our strategy and offerings are designed to support scientists in accelerating discoveries and expediting progress from basic research into clinical development.”

Key Exhibits Highlighted at SLAS2025

Some of the featured solutions at the event include:

• Assay Development and Automation: Custom automation solutions designed to enhance throughput, including the explorer™ G3 integrated workstation.
• Automated Liquid Handling: The Fontus™ liquid handler is equipped with user-friendly software and optimized protocols to streamline productivity.
• Cell Imaging and AI: Advanced imaging systems such as the Opera Phenix™ Plus HCS, which work in conjunction with the new Phenologic.AI technology.
• A Comprehensive Reagents Portfolio: This includes PhenoVue™ imaging reagents and CRISPR screening libraries from Dharmacon™.

Innovations in Research and Development

Visitors seeking detailed information about the showcased innovations, scientific talks, and poster sessions are encouraged to visit Booth #1318. This space will serve as a hub for insights into Revvity’s contributions to advancing research methodologies and understanding in life sciences.

About Revvity and Its Impact

Revvity is a transformative force within healthcare, dedicated to reimagining workflows from discovery through to development and diagnosis. The company focuses on multi-omics technologies, biomarker identification, imaging, and more, striving to redefine what's possible in the health sciences sector.

In 2023, Revvity achieved revenue exceeding $2.7 billion and boasts a robust workforce of over 11,000 employees. As a key player in the S&P 500 index, the company supports customers in pharmaceutical and biotech industries, academic institutions, and government organizations, operating in over 190 countries.

Frequently Asked Questions

What is Revvity's Phenologic.AI software?

Phenologic.AI is an innovative software designed to enhance cellular imaging workflows using advanced deep-learning models for image analysis.

Where will Revvity present its innovations?

Revvity will showcase its latest technologies at SLAS2025, held in San Diego from January 27-29.

What other products will be showcased alongside Phenologic.AI?

Revvity will also highlight Harmony™ 5.3 software and a variety of life sciences products for research and drug development.

How does Revvity support scientific research?

Revvity provides cutting-edge solutions and services designed to streamline workflows and facilitate advancements in scientific research and discovery.

What is the scale of Revvity's operations?

With over 11,000 employees and revenue surpassing $2.7 billion, Revvity supports a global customer base across various sectors.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.